Similar articles for PMID: 22429010

Year	Number of Results
2002	1
2004	4
2005	13
2006	8
2007	10
2008	13
2009	13
2010	18
2011	18
2012	21
2013	9
2014	11
2015	4
2016	5
2017	4
2018	4
2019	3
2020	2
2021	7
2022	3
2023	2
2024	0

1

Telmisartan in the management of diabetic nephropathy: a contemporary view.

Balakumar P, Bishnoi HK, Mahadevan N. Balakumar P, et al. Curr Diabetes Rev. 2012 May;8(3):183-90. doi: 10.2174/157339912800563972. Curr Diabetes Rev. 2012. PMID: 22429010 Review.

2

Telmisartan in incipient and overt diabetic renal disease.

Schmieder RE, Bakris G, Weir MR. Schmieder RE, et al. J Nephrol. 2011 May-Jun;24(3):263-73. doi: 10.5301/JN.2011.6416. J Nephrol. 2011. PMID: 21374585 Review.

3

Reduction of proteinuria with angiotensin receptor blockers.

Galle J. Galle J. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S36-43. doi: 10.1038/ncpcardio0806. Nat Clin Pract Cardiovasc Med. 2008. PMID: 18580865 Review.

4

The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.

Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S. Makino H, et al. J Int Med Res. 2005 Nov-Dec;33(6):677-86. doi: 10.1177/147323000503300610. J Int Med Res. 2005. PMID: 16372586 Free article. Clinical Trial.

5

Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.

Yamagishi S, Takeuchi M. Yamagishi S, et al. Med Hypotheses. 2005;64(3):476-8. doi: 10.1016/j.mehy.2004.09.015. Med Hypotheses. 2005. PMID: 15617852

6

Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.

Kusunoki H, Taniyama Y, Azuma J, Iekushi K, Sanada F, Otsu R, Iwabayashi M, Okayama K, Rakugi H, Morishita R. Kusunoki H, et al. Hypertension. 2012 Feb;59(2):308-16. doi: 10.1161/HYPERTENSIONAHA.111.176263. Epub 2012 Jan 17. Hypertension. 2012. PMID: 22252391

7

Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.

Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J. Ucciferri C, et al. Eur Rev Med Pharmacol Sci. 2012 Apr;16(4):491-8. Eur Rev Med Pharmacol Sci. 2012. PMID: 22696876

8

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators. Galle J, et al. Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. doi: 10.1093/ndt/gfn230. Epub 2008 May 1. Nephrol Dial Transplant. 2008. PMID: 18450829 Clinical Trial.

9

Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy.

Fujita H, Sakamoto T, Komatsu K, Fujishima H, Morii T, Narita T, Takahashi T, Yamada Y. Fujita H, et al. Hypertens Res. 2011 Dec;34(12):1302-8. doi: 10.1038/hr.2011.127. Epub 2011 Aug 4. Hypertens Res. 2011. PMID: 21814206 Clinical Trial.

10

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

Bichu P, Nistala R, Khan A, Sowers JR, Whaley-Connell A. Bichu P, et al. Vasc Health Risk Manag. 2009;5(1):129-40. Epub 2009 Apr 8. Vasc Health Risk Manag. 2009. PMID: 19436679 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

155 results

Results by year